NCT01835158 2021-02-11Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerNational Cancer Institute (NCI)Phase 2 Completed157 enrolled 10 charts 1 FDA